(Q37861216)

24 August 2017

1 reference

title

Current status and future applications of cellular therapies for cancer (English)

1 reference

24 August 2017

3

Angus Dalgleish

1 reference

24 August 2017

John Copier

1

1 reference

PubMed ID

21463192

24 August 2017

Mark Bodman-Smith

series ordinal

2

1 reference

24 August 2017

1 April 2011

1 reference

24 August 2017

1 reference

24 August 2017

3

1 reference

24 August 2017

4

1 reference

24 August 2017

507-516

1 reference

Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters

24 August 2017

1 reference

The evolving role of dendritic cells in cancer therapy

21 January 2018

1 reference

Dendritic cell vaccines in melanoma: from promise to proof?

21 January 2018

1 reference

Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon.

21 January 2018

1 reference

Dendritic cell preparation for immunotherapeutic interventions.

21 January 2018

1 reference

Tumor-induced modulation of dendritic cell function

21 January 2018

1 reference

T-regulatory cell modulation: the future of cancer immunotherapy?

21 January 2018

1 reference

Administration of cyclophosphamide changes the immune profile of tumor-bearing mice

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma

21 January 2018

1 reference

Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer.

21 January 2018

1 reference

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses

21 January 2018

1 reference

Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients

21 January 2018

1 reference

Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2.

21 January 2018

1 reference

Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial

21 January 2018

1 reference

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

Improving the efficacy of cancer immunotherapy

21 January 2018

1 reference

A clinical development paradigm for cancer vaccines and related biologics

21 January 2018

1 reference

Adoptive cell therapy for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL.

21 January 2018

1 reference

Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy.

21 January 2018

1 reference

Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients

21 January 2018

1 reference

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

21 January 2018

1 reference

Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination

21 January 2018

1 reference

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells

21 January 2018

1 reference

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

21 January 2018

1 reference

Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma

21 January 2018

1 reference

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

21 January 2018

1 reference

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

21 January 2018

1 reference

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

21 January 2018

1 reference

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.

21 January 2018

1 reference

The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders

21 January 2018

1 reference

Adoptive therapy using antigen-specific T-cell clones

21 January 2018

1 reference

Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones.

21 January 2018

1 reference

Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens

21 January 2018

1 reference

Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.

21 January 2018

1 reference

MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro

21 January 2018

1 reference

Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor

21 January 2018

1 reference

A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas

21 January 2018

1 reference

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma

21 January 2018

1 reference

Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo.

21 January 2018

1 reference

Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour

21 January 2018

1 reference

Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study.

21 January 2018

1 reference

A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells

21 January 2018

1 reference

Gammadelta T cells for immune therapy of patients with lymphoid malignancies

21 January 2018

1 reference

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer

21 January 2018

1 reference

In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients

21 January 2018

1 reference

Regression of melanoma metastases following treatment with the n-bisphosphonate zoledronate and localised radiotherapy.

21 January 2018

1 reference

The potential of immunomodulatory drugs in the treatment of solid tumors

21 January 2018

1 reference

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.

21 January 2018

1 reference

Immunotherapy for malignant melanoma--tracing Ariadne's thread through the labyrinth

21 January 2018

1 reference

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.11.18

1 reference

24 August 2017

1 reference

PubMed ID

21463192